glp-1 news updates New study confirms medications are safe for mental health in diabetes Two Weeks of GLP-1 News

Clinical characteristics of asymptomatic allergen sensitization with nasal septal deviation, often misdiagnosed as allergic rhinitis

GLP-1 receptor agonist therapies have become one of the fastest-growing segments in the global pharmaceutical market

These compounds are sold strictly for in vitro laboratory research and are not approved for human consumption.

If tests show deficiency, replacement is justified and often rapidly helpful

New England Journal of Medicine 2023 03 Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial Rosenstock J, Frias J, Jastreboff AM, et al

This combination is prepared in a precise 1:1 ratio to support research consistency